Keen Vision Acquisition Corporation (KVAC) to Combine with Medera in $622.6M Deal

Keen Vision (NASDAQ:KVAC) has entered into a definitive agreement to combine with clinical-stage biotech firm Medera at an enterprise value of $622.6 million. Boston-based Medera is developing a line of gene therapies to potentially treat rare cardiovascular ailments. The combined company is expected to trade on the Nasdaq once the deal is completed in the
Read More